Development of a Highly Selective Allosteric Antagonist Radioligand for the Type 1 Cholecystokinin Receptor and Elucidation of Its Molecular Basis of Binding

Understanding the molecular basis of ligand binding to receptors provides insights useful for rational drug design. This work describes development of a new antagonist radioligand of the type 1 cholecystokinin receptor (CCK1R), (2-fluorophenyl)-2,3-dihydro-3-[(3-isoquinolinylcarbonyl)amino]-6-methox...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Pharmacol
Main Authors: Dong, Maoqing, Vattelana, Ashton M., Lam, Polo C.-H., Orry, Andrew J., Abagyan, Ruben, Christopoulos, Arthur, Sexton, Patrick M., Haines, David R., Miller, Laurence J.
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society for Pharmacology and Experimental Therapeutics 2015
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4279081/
https://ncbi.nlm.nih.gov/pubmed/25319540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.114.095430
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados